Table 11.

Percentage of positive seroconversion among the treatment groups.

Seropositive Patients Were Excluded at Baseline (V2)
Patients Group	Amount	V4/5 Negative	V4/5 Positive	% of the Positive Patients	Asymptomatic Seroconversion	Symptomatic Seroconversion	Disease Incidents
Group 1 (RT23+)	353	282	71	20.1%	32	39	79
Group 2 (BCG)	168	128	40	23.8%	18	22	38
Group 3 (Placebo)	174	135	39	22.4%	13	26	44
Total amount	695	545	150	21.6%	63	87	161